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2ABSTRACT
Registries and biobanks in juvenile dermatomyositis have generated statistical power to help
understand pathogenesis and determine treatment and long-term outcomes in this rare and
heterogeneous disease. Genotype, autoantibodies, muscle histology and early clinical
features may predict prognosis and guide personalised treatment. While corticosteroids and
disease modifying anti-rheumatic drugs improve outcomes, there remain children who
experience refractory disease. Ongoing research into the aberrant immune response and
novel biological targets is necessary. Best practice guidelines promote prompt stepwise
treatment and there is growing appreciation of the role of exercise in improving prognosis.
Validated tools standardise assessment of disease activity and damage in musculoskeletal,
mucocutaneous, pulmonary, cardiac, gastrointestinal and endocrine systems. Recently, an
internationally agreed dataset for juvenile dermatomyositis has been defined for clinical
practice and incorporation into registries. In the future, with bigger datasets, statistical
models may guide stratification for personalised medicine and discern the most relevant
outcome markers for research.
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3[A] Introduction
Juvenile dermatomyositis (JDM) is a rare childhood autoimmune condition characterised by
inflammation of small vessels within the skin, muscle and major organs. Prognosis is
variable, ranging from monocyclic disease to chronic illness extending into adulthood with
substantial complications (1). There is increasing emphasis on early aggressive treatment to
improve long-term outcomes. However, response to drug therapies is unpredictable and
many drugs have adverse effects. For a ‘treat to target’ approach, it is important to
understand the underlying disease pathogenesis. Mounting evidence suggests genotype,




Until recently, small patient numbers and low statistical power have hampered research into
the genetic contribution of JDM. The international genetics consortium in myositis
(MYOGEN) has expedited international multicentre DNA sample and clinical data collection.
MYOGEN recently completed the first genome-wide analysis of idiopathic inflammatory
myopathies including children with JDM (2). Risk and protective alleles for JDM have been
identified within the human leukocyte region (HLA), cytokine genes and lymphocyte signaling
genes (Table 1). Notably, certain alleles are associated with more severe disease outcomes,
such as progression to calcinosis and ulceration.
[B] Autoantibodies
Autoantibodies are found in greater than 60% of children with JDM (5). Autoantibodies are
classified into myositis-specific autoantibodies (specific to myositis) and myositis-associated
antibodies (present in various autoimmune diseases). Each child typically carries a single
myositis-specific antibody (5) and children bearing the same antibody often share similar
4clinical features and long-term prognoses (Table 2). Certain JDM risk alleles are associated
with development of specific autoantibodies (3, 4), suggesting there might be distinct
genetic/serotypic JDM subsets exhibiting discrete disease trajectories.
[B] Immunohistopathology
Figure 1 summarises findings from studies to date exploring the humoral and cell mediated
immune mechanisms precipitating muscle damage in JDM. Muscle biopsy remains important
in the diagnosis of JDM, and many of the changes illustrated in Figure 1 can be detected on
biopsy. A validated tool has been developed to quantify and score the histological severity of
biopsies (9) with mounting interest in using this to predict disease course. Table 3 details a
number of histological features and correlation with disease phenotype. Ultimately, the most
powerful predictor of clinical outcome is likely to be a composite measure combining
genotype, autoantibody status and muscle histology score. This is illustrated in a recent
study that revealed histological severity predicted increased risk of remaining on treatment,
but anti-Mi-2 autoantibody provided a protective effect. Children carrying this antibody were
more likely to enter drug-free remission despite having severe disease marked on muscle
biopsy (6).
[B] Environment
It is possible that a number of environmental factors disrupt the immune system of
genetically susceptible children to trigger onset or influence disease course in JDM. Many
children suffer from infection prior to disease onset (12) and infection within six months of
illness onset increases risk of a polycyclic, rather than monocyclic, disease course (13).
Gene expression profiling has revealed a prominent type I interferon-signature in JDM
muscle that could be in keeping with viral exposure (14). Greater ultraviolet light exposure in
boys one month prior to diagnosis increases risk of a chronic, compared to polycyclic,
disease course (13). Uncovering environmental triggers could improve understanding of the
complex dysregulated immune response of JDM.
5[A] Treatment
To date, very few randomised controlled trials have been possible in JDM due to disease
rarity, hetereogeneity and lack of standardised tools to measure clinical outcomes.
Treatment decisions have been largely based on clinicians’ experiences, and vary between
centres. There is an ongoing duty to foster international collaborations to maximise basic
science, translational and clinical research to find the best drug for each child. Parallel to
developing personalised drug therapies, there is growing appreciation of the role of exercise
in the management of JDM and the importance of a multidisciplinary team to help children
achieve their potential in their school, home and social lives. Early intensive physiotherapy,
occupational therapy, podiatry and psychology input are essential in finding ways to allow
children to adapt to impairments associated with disease activity or damage, and to enable
regain of functional status once in remission.
[B] Guidelines
The Single Hub and Access point for Pediatric Rheumatology in Europe (SHARE) is an
initiative to optimise treatment regimens for children with rheumatological conditions. SHARE
recently published best practice guidelines for the investigation and treatment of JDM
derived from a validated systematic literature review and consensus meetings with
experienced paediatric rheumatologists. Based on these recommendations, a flow chart (15)
was established for the treatment of JDM (Figure 2).
The Children’s Arthritis and Rheumatology Research Alliance (CARRA), a network of
Paediatric Rheumatologists in North America, has also described three initial Consensus
Treatment Plans (CTPs) (16, 17) for the treatment of moderately severe JDM based on
expert opinion (Figure 3). The concept of Consensus Treatment Plans (CTPs) is to limit
6treatment practice variation to enable researchers to develop comparative effectiveness
studies. This is particularly important in rare diseases where evidence is limited and
randomised controlled trials are not possible due to small patient numbers. CARRA have
recently extended CTPs in JDM to include treatment of persistent skin rash and treatment of
skin predominant disease (18, 19).
Recent studies
Table 4 summarises the available evidence for drugs commonly used in the treatment of
JDM, highlighting the sparsity of evidence on which clinical practice is based.
[B] Current practice
A survey revealed the majority of North American paediatric rheumatologists use
corticosteroids with methotrexate for ‘typical’ JDM cases, although route and pattern of
corticosteroid use varies (21). Respondents stated a tendency to add intravenous
immunoglobulin (IVIG) in severe or refractory cases or those with marked cutaneous
manifestations. Hydroxychloroquine is chosen for children with mild disease or whose main
symptom is rash. Cyclophosphamide is principally reserved for children with ulceration or
lung disease (22). Similarly, a survey in the United Kingdom and Ireland has shown that
corticosteroids and methotrexate are often chosen as first line therapy, while
cyclophosphamide is used in severe disease, systemic involvement or cutaneous ulceration
(23). A cohort study collecting data between 1980 and 2004 revealed that while European
children were more frequently managed with high-dose intravenous methylprednisolone,
ciclosporin, cyclophosphamide and azathioprine, Latin American children with similar clinical
features, often received methotrexate and hydroxychloroquine (24). This study documented
a change in practice over time with increased use of intravenous methylprednisolone and
second-line drugs. Subsequently, a randomised controlled trial has clearly demonstrated that
addition of methotrexate or ciclosporin achieved better disease control than corticosteroids
7alone. Fewer adverse effects were seen with methotrexate compared to ciclosporin,
supporting the usual practice of using prednisolone and methotrexate as first line treatment
(25) (Table 4, Figure 2, Figure 3).
There has been an increasing focus on early aggressive treatment, with prompt stepwise
use of medications to achieve timely remission and reduce risk of complications from
disease and long-term drug toxicity (26). A recent survey in North America revealed
clinicians are selecting various biologics for recalcitrant disease (20) including rituximab
(most popular), abatacept, TNFα blockade, and tocilizumab. A randomised placebo phase 
design trial of rituximab in adults and children with dermatomyositis failed to reach primary or
secondary endpoints, but the overall response rate, steroid-sparing effect and re-treatment
response suggested that rituximab is efficacious for both muscle and skin disease (27, 28).
Further studies are essential to compare the safety and efficacy of these biological agents
(29-31).
[B] Adjunctive treatments
Children are taught to apply high-factor sunscreen daily as ultraviolet light can trigger JDM
flares (15). Long-term corticosteroids are associated with a number of complications, and
children may be co-prescribed calcium and vitamin D to reduce risk of osteoporosis (32) and
gastro-protective cover to reduce risk of gastrointestinal bleeding and perforation (8).
[B] Physiotherapy
It has been suggested that exercise might be able to attenuate chronic systemic
inflammation underlying pathogenesis of JDM (33). Microvascular disturbances within the
muscle might reduce perfusion during exercise (34), leading to submaximal exercise
capacity, lower muscle strength, poorer lung function and reduced quality of life (35).
Reduced physical activity can result in deconditioning, obesity, cardiovascular disease and
metabolic syndrome (8). This is of particular concern in children taking long-term
8corticosteroids and in subsets of JDM with lipodystrophy (associated with insulin resistance,
diabetes mellitus and hyperlipidaemia).
Using myometry, magnetic resonance imaging (MRI) and measurement of serum creatine
kinase (CK) / lactate dehydrogenase (LDH) levels, a study demonstrated that exercise did
not increase muscle inflammation in children with JDM (36). Subsequently, a longitudinal
study showed 12 weeks of twice-a-week aerobic and resistance training exercise for children
with mild chronic JDM improved muscle strength and function, bone density, aerobic
conditioning and quality of life (33). A more recent randomised controlled trial demonstrated
that a 12 week home exercise programme was safe and led to significant improvement in
long jump distance, number of push ups and parental child health assessment questionnaire
score, but statistical significance was not achieved between the two groups for maximal
oxygen uptake, isometric muscle strength and fatigue; possibly because patients were on
average leading active lifestyles with high baseline levels (37). Beyond childhood, 12 weeks
of moderate intensity aerobic training for adolescents and adults in remission has been
found to increase cardiovascular fitness and oxidative capacity (37).
[B] Psychological interventions
Children with JDM, siblings and parents are vulnerable to psychological distress and could
benefit from psychosocial assessments and interventions at disease onset and throughout
the illness course (38). In a recent study, parents of children with JDM reported difficulties in
family communication and functioning, and increased conflicts and worry (38). It has been
shown that children within families with poor family functioning have reduced ability to adjust
(39). This highlights the value of focusing psychological assessment and therapy on not only
the child but the entire family unit. Corticosteroid use has also been associated with anxiety,
low mood, hypomania and psychotic symptoms in susceptible individuals (40). Many
paediatric rheumatology services now have dedicated psychologists and social workers.
9Disease activity may impact school attendance, exam performance and disrupt friendships.
Without adequate support, this might limit educational and career prospects, impair the
ability to form social relationships and damage self-esteem. In one study examining
functional outcomes, three of the 65 patients studied reported failing a grade related to
missing school due to JDM (41). Subsequently, all 65 children within the cohort achieved
well educationally and reported that JDM did not interfere with employment.
[B] Long-term prognosis and management of complications
The variability of outcome in JDM makes discussions on prognosis challenging (1, 41, 42).
Furthermore, outcomes have evolved significantly due to early aggressive treatment with
corticosteroids, DMARDS and biologics. As a result, published long-term outcome data
might not accurately reflect the present JDM disease course. Currently identified risk factors
for chronic illness include longer duration of untreated disease and higher skin disease
activity at diagnosis, persistent Gottron’s papules at 3 and 6 months and periungal nailfold
capillary changes at 6 months after diagnosis, documented infection within six months of
diagnosis, abnormal subcutaneous fat signal on magnetic resonance imaging at diagnosis,
initial muscle biopsy showing extensive active myopathic changes, severe arteropathic
changes, severe capillary loss and muscle infarcts, and the presence of anti-p155/140 (anti-
TIF-1) and anti-Ro antibodies (4). In addition a recent study suggests that patients with
either anti-TIF-1 or anti-MDA-5 antibodies have a higher chance of still being on disease
modifying medication at 5 years (as a surrogate measure of chronicity or disease severity),
after diagnosis than those with anti-Mi-2 antibodies (6).
[C] Musculoskeletal and mucocutaneous
Long-term active muscle disease results in chronic muscle weakness or dysfunction, and
has been found in 34% of patients in a multicenter study across Europe and Latin America
(43). Chronic skin disease can lead to long-term damage such as cutaneous scarring or
atrophy, seen in 53% of patients (43).
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Reported prevalence of calcinosis in JDM cohorts is between 10 and 70% (44), influenced
by methods of data collection, length of follow up and changing treatment practices over
time. It occurs more often within 5 years post JDM onset but can range from time of onset to
many years after diagnosis (45). Predictors include African American race (44), male (46),
younger age of disease onset, having TNFalpha-308A or IL-1alpha-889C polymorphisms,
anti-NXP2 autoantibodies, delay in treatment, higher initial CK level, prolonged elevation of
muscle enzymes, higher disease activity 6 months post diagnosis (46), and longer duration
of disease (44). The SHARE consensus-based recommendations advise actively examining
for calcinosis by manual palpation, with the use of plain radiographs where necessary (15).
A number of treatment options for calcinosis have been explored including
immunosuppressants, drugs targeting calcium metabolism, and surgery; however no
intervention is reproducibly effective and evidence is limited to small case reports (44).
Furthermore, there is no scoring system to grade extent and severity of calcinosis.
Development of a tool may be helpful in determining efficacy of drugs and identifying
children at greatest risk of complications. Complications of calcinosis include pain, joint
contractures, and risk of infection from staphylococcal, streptococcal or mycobacterial
organisms if deposits break the skin surface (44). Over time, calcinosis can spontaneously
regress (most likely with inactive disease or superficial lesions) or enlarge (44). Consensus
guidance recommends a prompt stepwise increase in immunosuppressive medication in the
presence of calcinosis, since reports suggest that aggressive therapy may decrease the
incidence of calcinosis and aid regression of established lesions (18, 44).
Lipodystrophy occurs in 10-30% of patients (47, 48), most commonly five years after
diagnosis of JDM (49). Associations include joint contractures, calcinosis, muscle atrophy,
chronic continuous illness course and facial erythema (49). Erythroderma and the presence
of p155 autoantibody are associated specifically with generalised lipodystrophy.
Erythroderma is also associated with partial lipodystrophy, while panniculitis and dysphonia
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are associated with focal lipodystrophy (49). It has been suggested that MRI could be useful
in confirming diagnosis of lipodystrophy or monitoring response to treatment (49). Patients
with all types of lipodystrophy are at increased risk of hypertriglyceridemia and those with
generalised and partial disease have increased risk of insulin resistance and diabetes (49).
Complications include steatosis and ovarian enlargement (49). Acanthosis nigricans,
hypertrichosis and low leptin levels can be found in patients with generalised disease, while
fat redistribution is seen in partial disease (49). The most appropriate treatment of JDM-
associated lipodystrophy is not well established. Metabolic abnormalities in patients with
various forms of lipodystrophy respond to metabolic therapies such as troglitazone (50), but
further research is needed to study the safety and efficacy of metabolic therapies in JDM.
[C] Pulmonary
Children with JDM may suffer from interstitial lung disease (ILD) and respiratory muscle
weakness. Pulmonary involvement is reported early in the disease course and deteriorates
at times of high disease activity (51). ILD has been associated with the presence of anti-
MDA-5 autoantibodies (52) and elevated Krebs von den Lungen 6 levels (produced by type
II pneumocytes and respiratory bronchiolar epithelial cells) (53). Typical appearances on
high resolution computed tomography (CT) include linear atelectasis, micro-nodules, ground-
glass attenuation, expiratory trapping, thickening of bronchial walls, bronchiectasis, fibrosis
and consolidation (54). Pulmonary function tests can reveal either restrictive and obstructive
defects (54). Restrictive lung disease has been associated with a greater long-term damage
outcome (51). Respiratory muscle weakness does not appear to correlate with the Childhood
Myositis Assessment Scale (routinely assessed in clinic in some cohorts of patients) (54)
and by the time children exhibit respiratory symptoms, damage to lung parenchyma could be
irreversible. These issues underline the value of identifying children with pulmonary
involvement early.
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SHARE recommends all children with JDM should have pulmonary function tests including
carbon monoxide diffusion capacity at time of diagnosis with further testing (such as high
resolution CT chest) in those with restrictive disease (15). Results of pulmonary function
tests can be difficult to interpret in young children (15) due to difficulty in engaging them in
the test and limited reference data for this age group. The radiation risk of repeated CT
scanning needs to be considered (15). SHARE advise there is insufficient evidence to guide
on frequency of tests although clinicians should be aware of risk of lung involvement
particularly in children with high myositis damage index scores and those with anti-RNA
synthetase antibodies (15).
Children identified with ILD should be treated aggressively with a combination of
corticosteroids and immunosuppressant drugs (55). In acute disease with respiratory
insufficiency, treatment with cyclophosphamide or IVIG can be effective (23). It is necessary
to balance drug complications against deterioration of pulmonary function on an individual
basis, and there is ongoing need to investigate if these therapies improve long term
pulmonary as well as overall outcomes.
[C] Cardiac
Systolic and diastolic dysfunction has been observed in JDM and correlates with skin (not
muscle) disease activity at one year post JDM onset, and persists even when disease is
inactive (56). Long terms studies are needed to investigate clinical implications of pump
dysfunction and whether dysfunction is an early marker of systolic and diastolic failure.
Children with JDM have increased rates of hypertension and dyslipidaemia (57). There are
no studies to date on coronary artery disease in JDM; however it is possible that these
metabolic disturbances could accelerate coronary artery atherosclerosis, making young
adults with JDM more susceptible to ischaemic heart disease. Children with JDM have
increased prevalence of ECG abnormalities and reduced heart rate variability (thought to be
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an indicator of autonomic dysfunction linked to increased rate of cardiac events(58)) (57).
Pericarditis and myocarditis have also been reported in a small number of studies (57).
SHARE guidelines recommend ECG and echocardiography for all children with JDM (15).
Assessment of long axis strain and E/é (E, early diastolic transmitral flow; é, early diastolic
tissue velocity), as markers for systolic and diastolic involvement on echo have been
recommended (57). SHARE advise repeated investigations for those with hypertension, high
disease activity one year post diagnosis, long-term high corticosteroid burden or chronic
ongoing active disease, in addition to long term follow-up for high risk children. There is
currently insufficient evidence to recommend on frequency of investigations or length of
follow-up. Besides aggressive immunosuppression, there is limited experience on use of
cardiac drugs in JDM. Longitudinal follow-up is necessary to understand long term
implications of cardiac involvement, and safety and efficacy of treatments.
[C] Gastrointestinal
Risk of aspiration is greatest around the time of diagnosis or soon after when disease is at
its most severe, and does not always correlate with validated muscle weakness scores such
as the Childhood Myositis Assessment Scale (CMAS) or Manual Muscle Test (MMT) scores
(15). It is crucial that all children presenting with coughing during swallowing or nasal speech
have formal assessments (such as speech and language therapy assessment, video
fluoroscopy or barium studies) (15), particularly since pharyngeal involvement has been
associated with poorer prognosis (59). Nasogastric feeding may be necessary for short
periods to time to reduce risk of aspiration. Vasculitis and thromboses of vessels supplying
the gastrointestinal tract can lead to malabsorption and intestinal ulceration with perforation
in severe cases (60, 61). Ulceration and perforation can occur early or late in disease, even
when muscle and skin disease activity is mild (60, 62). Symptoms may include persistent or
severe abdominal pain with vomiting, haematemesis, constipation or bloody stools. In some
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cases abdominal pain can be the only symptom, and long-term corticosteroids can mask
abdominal signs, so careful assessment is needed (62). It has been suggested that
aggressive biological treatments and timely surgical interventions are important in reducing
mortality rate in ulceration and perforation (62).
[C] Endocrine
Growth failure is a feature of cumulative damage in JDM, and occurs in around 10% of
patients (46). Reduced bone mineral density (BMD) has been identified at diagnosis and
during disease course. Predictors include longer duration of untreated disease (63) and
lower weight (64). High disease activity, high-dose corticosteroids, reduced mobility during
muscle weakness, active avoidance of sunlight, anorexia, gastrointestinal vasculitis
impairing absorption of vitamin D and calcium, and ovarian failure associated with disease or
cytotoxic therapy are speculated to be associated with low BMD (64), but more studies are
necessary to investigate these associations. Peak BMD achieved in early adulthood is a
significant determinant of later life osteoporosis, so it is important to consider prophylaxis
with vitamin D and calcium (63). Older age of menarche compared to the general population
has been recognised in JDM, with higher follicle-stimulating hormone (lower ovarian
reserve), lower prolactin and higher progesterone (possible luteal dysfunction) (65).
Dysregulation of hormone levels could be associated with disease pathogenesis or
treatment with corticosteroids, which can interfere with the hypothalamic-pituitary-ovarian
axis. No difference in frequency of menstrual disturbances or development of secondary
sexual characteristics have been observed (65).
[C] Mortality
While overall mortality rate has significantly improved (falling from 30% (66) to less than 2%
(41)) since introduction of corticosteroids, DMARDS and novel biologics, the systemic
inflammatory response is still profound in some children with JDM, and for a small subset,
the resulting pulmonary, gastrointestinal or multisystem failure is fatal (67). Risk factors
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include delay to treatment, older age, severe disease activity at onset, and weight loss (67).
This reiterates the importance of close clinical monitoring and escalating
immunosuppressive treatments for children at risk.
[C] Future treatments
With significant investment into basic science, the enthusiasm and contributions of many
children (and parents) with JDM, and collaboration with the pharmaceutical industry, novel
targets and new therapies have been identified. Recent evidence suggested dysregulation of
interferon (IFN) in JDM (68). Janus Kinase (JAK) acts downstream of IFN, and JAK inhibitors
have been used to good effect in children with interferonopathies (some of these children
bear clinical features similar to JDM) (8). Use of JAK inhibitors in JDM is being trialed in
North America and Europe, and it is thought that children with evidence of chronic
endothelial injury may be most suitable for this therapy.
Cytotoxic T cell Lymphocyte Antigen-4 (CTLA-4), CD28 and CD86 are expressed on muscle
cells or inflammatory cells within muscles in inflammatory myopathies (8). Abatacept is a
CTLA-4 fusion protein that binds to CD80/CD86 present on antigen presenting cells,
preventing binding of CD80/CD86 to CD28 on T cells, inhibiting T cell activation. Abatacept
in combination with sodium thiosulfate was reported to control muscle and skin disease, stop
progression of calcinosis and reduce corticosteroid burden in a child with severe resistant
JDM (69). Currently, a trial of abatacept in refractory moderately active JDM is in progress in
the United States.
Serum IL-6 has been correlated with disease activity in JDM (68). Case reports of adults with
polymyositis and an adult with overlap syndrome identify improvement of skin and muscle
disease with tocilizumab (IL-6 receptor antibody) (8). To date, experience of tocilizumab in
JDM is very limited.
16
[A] Clinical monitoring
Regular monitoring in JDM is essential; management plans should be tailored to fluctuating
disease activity levels, evidence of disease damage, and the evolving psychosocial needs of
the developing child. A thorough history and examination, including muscle strength testing
and skin examination is necessary at diagnosis and at every encounter. There has been
increasing emphasis on frequent observation, early detection and prompt treatment of skin
disease even in the absence of muscle pathology (70). In view of its prognostic implications
(42), it is useful to review periungal capillary changes at each opportunity. While some
studies suggest nailfold capillary density is a marker of both skin and muscle disease activity
(71, 72), other researchers show end row capillary loss to correlate solely with skin disease
(70).
At diagnosis, full blood count, erythrocyte sedimentation rate, urea and electrolytes, liver
function tests, muscle enzymes, and autoantibodies are recommended (15). Serum muscle
enzymes can be indicators of disease activity, but often are normal, particularly later in
disease course (47). It is valuable to measure CK, LDH, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and, where available, adolase to maximise the chance of
finding at least one elevated enzyme. A number of sensitive disease activity biomarkers in
the peripheral blood are currently under investigation, including type I IFN gene and
chemokine levels, galectin, and IL-6, IL-8 and TNF levels (73).
Radiological investigations are helpful in determining extent of muscle disease and major
organ involvement. MRI (T2 weighted protocols), when reported by experienced radiologists,
may be useful in helping to monitor disease activity (74). A recently developed MRI scoring
tool designed for defining muscle inflammation was shown to be accurate for the single
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reader, but variable between individuals, so requires further validation before this can be
incorporated into clinical practice (74).
Clinical and research tools are available to help quantify muscle and skin disease, major
organ involvement, functional ability and quality of life. These standardised assessments of
disease activity (reversible aspects related to active inflammation) and damage (irreversible
scarring from repeated inflammation or secondary to treatment) are useful for monitoring
disease over time. They can help guide decisions on treatment escalation or reduction, and
streamline data collection to facilitate collaboration and meta-analyses (75). Many of these
tools were initially designed for research purposes within Paediatric Rheumatology
International Trials Organisation (PRINTO) (76) and International Myositis Assessment and
Clinical Studies Group (IMACS) (76) core sets (Table 5), but now are increasingly being
incorporated into clinical practice. Recently, IMACS and PRINTO have engaged in a joint
effort to develop validated response criteria for JDM, including criteria for minimal, moderate
and major clinical response, allowing either IMACS or PRINTO core set measures to be
used, thus resolving the differences between IMACS and PRINTO core sets (76).
[B] Disease activity tools
[C] Clinician-completed
[D] Muscle
CMAS and MMT are validated examination tools for assessing muscle disease. CMAS uses
14 maneuvers to measure strength, function and endurance (77). As for many assessments
in children, thresholds for active disease may need to be adjusted according to the child’s
age, as it has been shown that healthy children up to 9 years may not always achieve the
maximum CMAS score (78, 79). Total MMT is an extensive assessment of 26 bilateral
muscle groups. Recently, this has been condensed to MMT8 (measurement of 8 axial,
proximal and distal muscles unilaterally that correlates well with total MMT) for practical use
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within the busy clinical environment (80). CMAS and MMT share many similarities, and there
is potential to investigate for redundancy between these tools and to validate a combined
shortened tool for clinical practice.
[D] Skin
Many tools have been used to assess extent of skin involvement, although it is yet to be
determined which tool is most accurate and reliable in JDM. The Cutaneous Assessment
Tool (CAT) measures the full range of skin activity and damage, and has been partially
validated in a large JDM cohort demonstrating good reliability (81). An abbreviated CAT
performs similarly to the full CAT, and is favoured in clinical practice (81). A recent study
comparing the CAT, skin DAS and MITAX tools for assessing skin in JDM suggested a new
tool may be required which incorporates all aspects of skin disease (82). The modified
Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI - Version 2)
evaluates 3 disease activity measures (erythema, scale, erosion/ulceration) and 2 damage
features (poikiloderma, calcinosis) as well as activity and /or damage due to Gottron’s
patches, periungal changes and alopecia. A recent study compared the CDASI and CAT in
JDM (n=14) and found both tools to be reliable when used by paediatric dermatologists or
rheumatologists (83).
[D] Global
The Myositis Disease Activity Assessment Tool (MDAAT) integrates the Myositis Disease
Activity Assessment Visual Analogue Scale (MYOACT) and Myositis Intention to Treat
Activities Index (MITAX). It appraises in detail disease activity in muscle, skin, and several
extra-muscular/extra-cutaneous systems (skeletal, gastrointestinal, pulmonary, cardiac and
constitutional), and has been shown to have good validity and reliability (77). The Disease
Activity Score (DAS) assesses overall muscle and skin disease activity; reported as separate
or combined muscle and skin scores (where there is approximately equal weighting between
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the two systems). DAS is thought to sensitively detect clinically important changes in disease
activity over time, although the sensitivity and specificity may diminish in children with the
most severe damage (77). Physician Visual Analogue Scale (VAS) is a global judgement
based on all the information available at the time of evaluation including history,
examination, blood results, and prescribed medications. It has good validity and reliability
and responsiveness in longitudinal monitoring (77).
[C] Patient-completed
[D] Global
Patient/parent VAS is a global judgement made by the older child or parent based on
disease activity in muscle, skin and major organs. Notably, physician VAS and patient VAS
are not collinear (84), reflecting the contrasting emphasis placed by clinician and patient on
different facets of a very multidimensional disease. The Childhood Assessment
Questionnaire (CHAQ) is a quick and simple instrument that measures overall wellbeing,
physical function, pain intensity and disability. It has good reliability and validity and
responsiveness; therefore suitable for longitudinal monitoring (77). However, this tool has
floor (scores cluster near zero in mild disease) and ceiling effects (does not distinguish
between activity and damage resulting in poor sensitivity and specificity for children with
most severe damage) (77, 85).
[D] Quality of life
A large number of quality of life tools are available, and in recent years, instruments
specifically tailored to the needs of children with JDM are emerging. The Child Health
Questionnaire (CHQ) is a widely used set of questions, validated for use in JDM, assessing
physical and psychological wellbeing, ability to participate in activities of daily living, and
psychosocial effects on the family (77). The Juvenile Dermatomyositis Multidimensional
Assessment Report (JDMAR) is JDM-specific tool currently undergoing further validation. Its
aims to assess function, quality of life, fatigue and treatment adverse effects (86).
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[B] Disease damage tools
The Myositis Damage Index (MDI) is a clinician-based assessment that has been partially
validated in JDM (77). It is a useful measure of global damage secondary to chronic
inflammation and drug toxicity. It scores the severity of long-term damage in different organ
systems including muscle, skin, gastrointestinal, pulmonary, cardiac, peripheral vascular and
endocrine systems, eyes, as well as occurrence of infection and malignancy. This tool has
been useful in facilitating understanding of long-term outcomes of JDM, and has highlighted
that a considerable number of adolescents and adults with JDM suffer from moderate to
severe damage as a result of chronic inflammation (1, 43, 46).
[B] Remission criteria
PRINTO have established data-driven criteria for clinically inactive disease (CID) to guide
clinical practice and research (87). Patients are classified as having CID if they obtain at
least 3 out of 4 variables of CPK ≤150, CMAS ≥48, MMT ≥78, and physician global 
assessment (PGA) ≤0.2. However, since 3 of these variables are muscle specific, this score 
may underestimate skin involvement. It has been suggested that PGA should be an
essential criterion when defining CID to avoid this (88).
[B] Registries and common datasets
Through a robust consensus process, an internationally agreed dataset for JDM has been
defined, along with an accompanying glossary of definitions, for use in clinical practice (89).
The aim is for this to be incorporated into existing national and international research
registries to allow comparison of data between groups. The development of registries is a
smart strategy to build statistical power, maximise yield from precious patient data and
samples, save on overall research costs, increasing efficiency and accelerating acquisition
of knowledge in a rare and heterogeneous disease (90, 91). Registries aid identification of
patients for interventional trials, are an important resource in epidemiological research, help
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estimation of disease burden, determination of long-term comorbidities including rare events,
and provide quality assurance in safety of medications. When linked to biobanks, they
facilitate identification of prognostic markers of disease and understanding of sub-
phenotypes (90, 91). Registries could also be beneficial in clinical practice; those that are
easily accessible and have user-friendly interfaces are valuable aid memoirs for assessing
patients in clinic, particularly for trainees less familiar with JDM.
The Juvenile Dermatomyositis Cohort and Biomarker Study and Repository (UK and Ireland)
has facilitated research by collecting prospective clinical data linked to serial biological
sampling (92). Projects led by group members and outside investigators have included work
on genetics, autoantibodies, muscle biopsy pathology, imaging studies, exercise, and
therapeutic targets in JDM. CARRA has developed a multicentre registry in the United
States and Canada for paediatric rheumatic diseases and is in the final stages of including
JDM (https://carragroup.org/). Euromyositis is web-based registry and biobank for adults and
children with inflammatory myopathies in Europe that also welcomes applications
internationally (93).
[B] Statistical models
As registry databases are collating growing numbers of observations and variables,
paediatric rheumatologists are encountering new challenges in data cleaning, preparation
and analysis, but also finding opportunities to explore novel research methods. A recent
study explored the possibility of modelling longitudinal outcomes in JDM (94). Using data
from almost 3000 clinic visits, clinical markers and symptoms were used as covariates in a
regression model to predict disease activity outcomes. In the future, with bigger datasets and
increasingly reliable models, statistical models may play a revolutionary role in stratifying
children for personalised medicine and maximising research efficiency through discerning
the most relevant outcome markers for research studies (94).
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[A] Summary
Advances in genetics, immunology and histology are accelerating understanding of JDM
pathogenesis, influencing management, and improving prognosis. MSAs and muscle
biopsies are now routinely taken in specialist centres and used alongside standard
assessments to guide treatment. Further research is needed to develop tools (combining
genotype, autoantibody status and muscle histology) to predict drug response and long-term
complications. Understanding aberrant immune pathways has facilitated the introduction of
several biologics off-label, which have significantly improved outcomes for some children.
Where expectations are evolving towards sustained clinical disease inactivity for every child,
ongoing studies are necessary to identify novel targets for children with recalcitrant disease,
and to compare safety and efficacy of drugs. In this rare and heterogeneous disease,
national and international collaborations and registries (with linked biobanks) have been
pivotal in driving research progress that was previously hampered by low statistical power.
Over recent years, multicentre collaborations have defined genetic/serotypic disease
subtypes, exposed new therapeutic targets, explored novel imaging techniques, and
determined the role of exercise in the management of JDM. A new challenge researchers
face is how to exploit the full potential of increasingly large volumes of data accumulating in
registries. There is mounting interest in integrating clinical practice and research to maximise
efficiency. Recently, an internationally agreed dataset for JDM for use in clinical practice was
defined, with the aim to facilitate data comparison if incorporated into registries. While
impressive advances have been achieved, subsets of children continue to experience active
disease into adulthood. There is an ongoing duty to foster international collaborations to




 Early aggressive treatment with stepwise use of a combination of corticosteroids,
disease modifying anti-rheumatic drugs and biologics could achieve early remission
and reduce risk of complications from disease and long-term drug toxicity
 Frequent observation, early detection and prompt treatment of skin disease even in
the absence of muscle pathology has prognostic importance
 Using consensus treatment plans during daily clinical practice could limit treatment
practice variation to facilitate development of comparative effectiveness studies
 Exercise programmes are safe and could improve muscle strength and function,
aerobic conditioning and quality of life in children with JDM
 Children with JDM, their siblings and parents could benefit from psychosocial
assessments and interventions at disease onset and throughout illness course
 Disease activity and damage tools standardise assessment of muscle and skin
disease, major organ involvement, functional ability and quality of life, and are helpful
in guiding decisions on treatment
[A] Research Agenda
 Genotype, autoantibody status, muscle histology score and early clinical features
should be important biomarkers to predict disease prognosis and guide personalised
treatment
 Reliable, sensitive and easy to measure biomarkers are needed to monitor disease
activity. Peripheral blood levels of Type I IFN gene and chemokine levels, galectin,
IL-6, IL-8 and TNF are potential candidates
 Further research is necessary to find novel biological targets for children with
recalcitrant disease, and to compare safety and efficacy of biological agents. JAK
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inhibitors and Abatacept are being trialled in JDM and could be beneficial for certain
genetic/serotypic subsets of patients
 Registries should not only be useful in building statistical power for research but also
facilitate daily clinical practice such as acting as aid memoirs for assessing patients
 Incorporation of the newly defined internationally agreed dataset for JDM into clinical
practice and existing registries will facilitate comparison and merging of data between
groups
 With larger datasets, modelling of longitudinal outcomes, stratification of children for




Fig 1. Evidence for mechanisms contributing to juvenile dermatomyositis pathogenesis. (3,
4, 8)
[Footnote - Figure 1 ]: pDC: plasmacytoid dendritic cell; c’: complement; Treg: regulatory T cell; IL: interleukin; MCP:
monocyte chemoattractant protein; IFN: interferon; MHC: major histocompatibility complex; CXCL: Chemokine (C-X-C motif)
ligand; MRP: myeloid-related protein; TLR: toll-like receptor; MAC: membrane attack complex; ICAM: intercellular adhesion
molecule; VCAM: vascular cell adhesion molecule
Fig 2. Flow chart adapted from Single Hub and Access point for Paediatric Rheumatology in
Europe (SHARE) recommendations for treatment of juvenile dermatomyositis. Adapted from
(15)
[Footnote - Figure 2]: IV: intravenous; PO: oral; MTX: methotrexate; IVIG: intravenous immunoglobulin; DMARD:
disease modifying anti-rheumatic drug; MMF: mycophenolate mofetil
Fig 3. Flow chart adapted from Children’s Arthritis and Rheumatology Research Alliance
(CARRA) Consensus Treatment Plans (CTPs) for treatment of moderately severe juvenile
dermatomyositis. Adapted from (16, 17)
[Footnote – figure 3]: MP: methylprednisolone; IV: intravenous; MTX: methotrexate; SC: subcutaneous; PO: oral; IVIG:
intravenous immunoglobulin; MRI: magnetic resonance imaging; EMG: electromyography; PGA: physician global assessment;
CMAS: Childhood Myositis Assessment Scale; MMT; manual muscle testing; GI: gastrointestinal; ICU: intensive care unit; CNS:
central nervous system; MMF: mycophenolate mofetil; AZA: azathioprine.
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Table 1. Risk and protective alleles for juvenile dermatomyositis. (3, 4)
Risk alleles Alleles associated with more severe
disease
Protective alleles
HLA-B*08 TNFα-308A  HLA-DQA1*0201 




TNFα-238GG   
TNFα-308AG   
IL-1α+4845TT   






HLA: human leucocyte antigen; TNF: tumour necrosis factor; IL: interleukin; IgH: immunoglobulin heavy chain;
Ptpn: protein tyrosine phosphatase; CCL: chemokine c-c motif ligand; PLCL: phospholipase c-like; BLK: B
lymphoid kinase
Table 2. Autoantibodies identified in juvenile dermatomyosistis and associated phenotypes and alleles. (4-7)









Highest prevalence in white race
Younger age group (median age = 7
years)
 Cutaneous ulceration
 Greater muscle weakness (CMAS)
Anti-NXP2
(Anti-MJ)
Nuclear matrix protein 2 15-25%
Highest prevalence in white race
Younger age group (median age = 6
years)
 Younger age of disease onset




6-38%  Mild disease
 Cutaneous ulceration
 Arthritis





Larger proportion of non-white patients –
mostly Hispanic
Older age group (median age = 11 years)
 Severe muscle disease






6-8% in European cohorts
~ 2% in Asian cohorts
 Predominant cutaneous involvement












Larger proportion of non-white patients
Older age of onset (median age = 14
years)
 Anti-synthetase syndrome: ILD, Raynauds, arthritis, fever,
mechanics hands & rash
 Lipoatrophy
 Anti-Jo-1: Increased frequency of myositis, arthralgia &
mechanic’s hands
 Non-Jo-1 ASA-positivity: Increased frequency of DM skin
lesions, fever & ILD
Ha, Anti-Zo)
Anti-SRP Signal recognition particle 2% JDM
Increased prevalence in Black race
Older age of onset (median age = 15
years)
 More likely to be classified as JPM
 Severe necrotising myopathy
 Chronic disease course
Anti-HMGCR 3-hydroxy-3-methylglutaryl-
coenzyme A reductase
~ 1% JDM  More likely to be classified as JPM
 Increased risk of muscle weakness, & dysphagia
M
A





 Associated with poorer prognosis with decreased functional
status with long-term follow up
Anti-La (SSB) Ribonucleoprotein 2-12% myositis overlap  No significant associations described in IIM
Anti-U1-RNP U1 ribonucleoprotein
(snRNP)
3-8% JDM / JPM
25-40% myositis overlap
 Polymyositis / polymyositis overlap phenotype
 Older age at disease onset. Less likely to be weak
Anti PM-Scl Nucleolar multi-protein
complex
3-5%  Myositis overlap, most commonly scleroderma overlap
features
 Risk of ILD, arthritis, Raynaud’s
 Association described with calcinosis & lipoatrophy
Anti-Ku p70/p80 heterodimer,
DNA-associated proteins
9-19% pateints with myositis overlap  CTD overlap
 Increased arthralgia, Raynaud’s, ILD & musculoskeletal
manifestations
MSA: myositis specific antibodies; MAA: myositis associated antibodies; ILD: interstitial lung disease; IIM: idiopathic inflammatory myopathies; JPM: juvenile polymyositis;
JDM: juvenile dermatomyositis
Table 3. Muscle biopsy features and associated phenotype. (10, 11)
Muscle biopsy Clinical features
Lymphoid follicles including networks of fDCs and high endothelial
venules
High levels of CXCL13 and lymphotoxins








Chronic disease course with
ulceration
Extensive active myopathic changes
Central nuclei without basophilia
Chronic disease course
fDC: follicular dendritic cells; CXCL13: C-X-C Motif Chemokine Ligand 13; pDC: plasmacytoid dendritic cells








newly-diagnosed, retrospective, non-randomised, with propensity score matching
IV or PO CS 5-30mg/kg/d (n=42 of total 76 matched)
CS 1-2mg/kg/d (n=42 of total 63 matched)







PO CS 2mg/kg/d (n=5)
IV CS high-dose with PO CS 0.5mg/kg/d (n=5)





IV CS 20mg/kg/d for 3-6d then twice a wk for 2-5wk




PO CS 50mg/m2 on d 1
IV CS on d 2
AUC of IV CS greater than PO CS but not significant difference. Inverse association between difference of AUC between IV and PO CS and
nailfold ERL





newly-diagnosed, no previous treatment, no cutaneous / GI ulceration
prednisolone alone (n=47)
prednisone + CiA (n=46) OR prednisone + MTX (n=46)
at 6mo, 51% of prednisone, 70% of prednisone + CiA, and 72% of prednisone + MTX achieved improvement. More patients on prednisone + CiA




consecutive patients in clinic before and after date of new policy of first-line therapy with MTX, non-randomised, retrospective
MTX 10–20mg/m2/wk + PO prednisolone 2mg/kg/d, at 6 wks if muscle enzymes reduced + improved clinically, prednisone tapered by ∼10%
every 2 wks (n=31)
PO prednisolone 2mg/kg/d, at 6 wks tapered by ∼10% every mo (n=22)
study group had approximately half cumulative prednisolone dose, greater height velocity during 1st yr of treatment, smaller BMI increase in 1st 2
yrs, longer time to development of cataracts
case series P n=16, recalcitrant disease
IO
MTX + PO prednisone
all 12 patients who received MTX for at ≥8mo regained normal muscle strength. In 11/12 patients, prednisone tapered to ≤5mg/day. Active 





CS + MTX (n=3) or CS + MTX + AZA (n=2)





9-31mo with PO prednisolone + IV MTX
at 3mo, clinical improvement + reduction of prednisolone dose. 3 patients recovered, 1 patient died. Adverse effects: elevated liver enzymes,
nausea, abdominal pain, bone pain, mild neutropenia, mild pruritis




n=5 (+17 JIA patients)
CiA mean dose 3.2mg/kg/d over mean period 16mo
prednisone stopped in 5/20 patients and reduced by >50% in 10/20 patients. No hepatic or bone marrow toxicity or lymphoproliferative disease
P n=3 (+9 JIA patients), not responded to CS +/or cytotoxics
IO
CiA mean dose 5mg/kg/d over 9-48mo
treatment effective. Adverse effects: alopecia, hypertension, hypertrichosis, tremors, hirsutism. 1 JIA patient developed polyserositis with




n=14, not responded to CS + other immunosuppressants
CiA
CS stopped or reduced in all patients. Regain of muscle strength and function. No serious adverse effects











decrease in mean sDAS, mDAS, prednisone dosage. WBC count unchanged. No difference in infection rate between 12mo pre-treatment period
and 1st 6mo of MMF, infection rate decreased in 2nd 6mo of MMF (infection rate studied in n=26 subset who were observed for 12mo before start
of MMF)





Juvenile Dermatomyositis Cohort and Biomarker Study and Repository (UK and Ireland)
CYC 500mg/m2 every 2wk for 1st 3 doses then 750mg/m2 every 3-4wks for total 6-10 doses (n=83)
remaining patients (with less severe disease) in cohort did not receive CYC (n=442)
at 24mo, improvement in PGA, mDAS, CMAS and MMT8. No serious adverse effects. Ongoing analyses on disease trajectories of patients




n=12, severe and refractory disease
CYC
at 6mo, 83% had improved muscle function and strength, LDH, skin disease, global extramuscular disease. No severe adverse effects.
Reversible complications: lymphopenia, herpes zoster infection, alopecia. 2 patients with severe refractory disease died after 1 dose of CYC
(thought to be result of severe disease)
HCQ case series P
I
O
n=9, not responded to CS / exacerbation when tapering CS
HCQ mean dose 3.6mg/kg/d
at 3mo, improvement in rash, proximal and abdominal muscle strength
expert opinion high dose + long duration of HCQ use are risks for ocular toxicity, maximum dose should be ≤5.0mg/kg/d real weight, annual screening 
recommended
TAC case series P
I
O
n=3, refractory extensive skin disease, severe muscle weakness, CS dependent
TAC






retrospective, marginal structural modelling to account for confounding by indication
IVIG (these patients had weaker muscle strength and more photosensitivity) (n=30)
no IVIG (n=48)




n=9, not responded / severe side effects to conventional treatment
IVIG









n=18, not responded to IVIG or steroid toxicity
IVIG




n=5, not responded to CS / other immunosuppressive therapy toxicity
IVIG
improved muscle strength and skin rash. CS stopped or dose reduced





adults with refractory PM + adults and children with refractory DM
RTX at wk 0 (n = 93)
RTX at wk 8 (n = 102)
no difference in time to achieve IMACS group DOI between 2 groups. However, 83% patients with refractory disease met DOI
cohort P
O
retrospective analysis of RCT above
anti-Jo-1 and anti-Mi-2 autoantibody predicted shorter time to improvement. JDM demonstrated trend toward better clinical improvement
compared to adult subgroups (p=0.06) prior to wk 20
case series P n=9, severe +/or refractory muscle involvement, severe calcinosis, abdominal lipomatosis
IO
RTX
complete response achieved in 3/6 patients treated for muscle involvement, where CS stopped or tapered to <15% of baseline. No improvement




Juvenile Dermatomyositis Cohort and Biomarker Study and Repository (UK and Ireland)
anti-TNF agents (n=66)
improvement in muscle and skin disease. 21 adverse effects (including 7 severe = anaphylaxis on IFX). 1 patient died due to small bowel





IFX IV 3mg/kg at 0, 2, 6, 8wks
improvements in pVAS, CMAS, CHAQ, joint range of movement. In some children, regression of calcinosis and skin signs. No major
adverse effects





ETN 0.4mg/kg SC twice weekly for 12 wks and followed up for 12 wks after last dose ETN
At 24wks, 1 patient stable, 2 patients had worsening DAS, 3 patients had improved DAS. Trend of worsening NFC at wk 12 and improvement at
wk 24. No change in muscle enzymes or CMAS. 1 patient stopped after 5th ETN dose (marked worsening of rash).
P: population; I: intervention; C: comparison; O: outcome; RCT: randomised controlled trial; CS: corticosteroid; IV: intravenous; PO: oral; d: day; yr: year; wk: week; AUC: area under curve; ERL:
end row loops; MTX: methotrexate; CiA: ciclosporin; mo: month; BMI: body mass index; AZA: azathioprine; JIA: juvenile idiopathic arthritis; MMF: mycophenolate mofetil; sDAS: skin disease activity
score; mDAS: muscle disease activity score; WBC: white blood cell; PGA: physician global assessment; CMAS: childhood myositis assessment score; MMT8: manual muscle testing 8; CYC:
cyclophosphamide; LDH: lactate dehydrogenase; HCQ: hydroxychloroquine; TAC: tacrolimus; IVIG: intravenous immunoglobulin; RTX: rituximab; IMACS: International Myositis Assessment and
Clinical Studies Group; DOI: definition of improvement; JDM: juvenile dermatomyositis; IFX: infliximab; pVAS: physician visual analogue scale; CHAQ: childhood health assessment questionnaire;
ADA: adalimumab; ETN: etanercept; SC: subcutaneous; NFC: nailfold capillary
Table 5. Comparison of Paediatric Rheumatology International Trials Organisation and
International Myositis Assessment and Clinical Studies Group core response variables. (76)
PRINTO IMACS
disease activity measures completed by clinician
Muscle CMAS (or MMT) MMT
- ≥2 of CK, adolase, LDH, 
AST, ALT
Skin - -
Global DAS (or MDAAT) MDAAT
physician global activity physician global activity








PRINTO: Paediatric Rheumatology International Trials Organisation; IMACS: International Myositis Assessment
and Clinical Studies Group; CMAS: Childhood Myositis Assessment Scale; MMT: Manual Muscle Test; CK:
creatine kinase; LDH: lactate dehydrogenase; AST: Aspartate transaminase; ALT: Alanine transaminase;
MDAAT: Myositis Disease Activity Assessment Tool; DAS: Disease Activity Score; CHAQ: Childhood
Assessment Questionnaire; CHQ: Child Health Questionnaire.
